Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) on February 22, 2017. The company is a biopharmaceutical entity focused on neurogenic small molecule programs, specifically for the treatment of major depressive disorder.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance.
Material Changes
On February 22, 2017, the United States Patent and Trademark Office issued US Patent No. 9572807. This patent covers NSI-189, the Company's lead compound in its neurogenic small molecule program.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the patent issuance. The primary event is the strengthening of the company's intellectual property portfolio regarding its lead therapeutic candidate.
Investor Verification Checklist
- Verify the scope and claims of US Patent No. 9572807 for NSI-189.
- Confirm the current clinical development status of NSI-189 for major depressive disorder.
- Review the attached press release (Exhibit 99.01) for additional details on the patent's commercial implications.